Episode Details

Back to Episodes
Pharmaceutical Executive Daily: FDA Approves Tecentriq

Pharmaceutical Executive Daily: FDA Approves Tecentriq

Published 1 month, 1 week ago
Description
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us